Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, International, Prospective, Non-interventional, Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

NCT05633771 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT05633771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, International, Prospective, Non-interventional, Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Lead sponsor
Sandoz
Phase
Observational
Overall status
Active, not recruiting
Start date
February 16, 2023
Completion date
December 31, 2026
Enrollment
562 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease